Last reviewed · How we verify
exenatide/insulin glargine
At a glance
| Generic name | exenatide/insulin glargine |
|---|---|
| Also known as | Byetta, AC2003, syntheitc exenden-4 |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- New Onset Type 1 Diabetes: Role of Exenatide (PHASE4)
- Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- exenatide/insulin glargine CI brief — competitive landscape report
- exenatide/insulin glargine updates RSS · CI watch RSS
- AstraZeneca portfolio CI